Literature DB >> 16904048

An evaluation of the clinical and cost-effectiveness of pulmonary artery catheters in patient management in intensive care: a systematic review and a randomised controlled trial.

S Harvey1, K Stevens, D Harrison, D Young, W Brampton, C McCabe, M Singer, K Rowan.   

Abstract

OBJECTIVES: To evaluate the clinical and cost-effectiveness of managing critically ill patients in adult, general intensive care with or without pulmonary artery catheters (PACs).
DESIGN: An open, multi-centre, randomised controlled trial with economic evaluation (cost-utility and cost-effectiveness analysis).
SETTING: The setting was general (mixed medical/surgical) intensive care units (ICUs) in the UK admitting adults. PARTICIPANTS: Adult patients in participating ICUs deemed by the responsible treating clinician to require management with a PAC.
INTERVENTIONS: These were insertion of a PAC and subsequent clinical management, at the discretion of the responsible treating clinicians, using data derived from the PAC. The control group were managed without a PAC but with the option of using alternative cardiac output monitoring devices. MAIN OUTCOME MEASURES: The main outcome measure was hospital mortality. Secondary outcome measures were length of stay in the ICU, length of stay in an acute hospital and organ-days of support in the ICU. For the economic evaluation, the main outcome measure was quality-adjusted life-years (QALYs) and the secondary outcome measure was hospital mortality.
RESULTS: Sixty-five ICUs in the UK participated. Of these, 43 (66%) used alternative cardiac output monitoring devices in control group patients. A total of 1263 patients were identified as being eligible for the trial. Of these, 1041 (82.4%) were randomised and allocated to management with (n = 519) or without (n = 522) a PAC. There were no losses to follow-up. However, 27 patients (13 in the PAC group and 14 in the control group) were withdrawn from the trial because either the patient withdrew consent on recovering mental competency or the relatives withdrew agreement following randomisation. Data on 1014 patients were included in the analysis. Participants in the two groups had similar baseline characteristics. There was no difference in hospital mortality for patients managed with (68.4%) or without (65.7%) a PAC. The adjusted hazard ratio (PAC versus no PAC) was 1.09 [95% confidence interval (CI) 0.94 to 1.27]. There was no difference in the median length of stay in ICU, the median length of stay in an acute hospital or mean organ-days of support in ICU between the two groups. The economic evaluation found that the expected cost per QALY gained from the withdrawal of PAC was 2985 pounds. The expected cost per life gained from the withdrawal of PAC was 22,038 pounds.
CONCLUSIONS: Clinical management of critically ill patients with a PAC, as currently practised in the UK, neither improves hospital survival for adult, general intensive care patients nor reduces length of stay in hospital. The lack of demonstrable benefit from a device previously believed to be beneficial could be explained by statistical chance, by misinterpretation of PAC-derived data, by ineffective treatment strategies based on data correctly interpreted using the current paradigm or by subsequent inaction following insertion of the device. It is also possible that detailed data on haemodynamics, however used, cannot modify the disease process sufficiently to influence disease outcome. The economic evaluation, using decision analysis techniques rather than conventional hypothesis testing, suggests that the withdrawal of the PAC from routine clinical practice in the NHS would be considered cost-effective in the current decision-making climate, and might result in lives or life-years being saved at modest cost. With the declining use of PACs in the UK and the findings of this report indicating no overall benefit from management with a PAC, it should now be possible to examine protocolised management with a PAC in selected groups of critically ill patients against appropriate controls, something that was difficult while PACs were the considered standard of care.

Entities:  

Mesh:

Year:  2006        PMID: 16904048     DOI: 10.3310/hta10290

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  17 in total

1.  Pulmonary artery catheters.

Authors:  Simon Finfer; Anthony Delaney
Journal:  BMJ       Date:  2006-11-04

2.  Health technology assessment in critical care.

Authors:  Damon C Scales; Andreas Laupacis
Journal:  Intensive Care Med       Date:  2007-10-20       Impact factor: 17.440

Review 3.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Hemodynamic monitoring development: helpful technology or expensive luxury?

Authors:  Karim Bendjelid
Journal:  J Clin Monit Comput       Date:  2012-10       Impact factor: 2.502

5.  Passive Self Resonant Skin Patch Sensor to Monitor Cardiac Intraventricular Stroke Volume Using Electromagnetic Properties of Blood.

Authors:  Fayez Alruwaili; Kim Cluff; Jacob Griffith; Hussam Farhoud
Journal:  IEEE J Transl Eng Health Med       Date:  2018-09-26       Impact factor: 3.316

6.  Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients.

Authors:  Mariska Y M Peeters; Leon P H J Aarts; Ferenc A Boom; Leo J Bras; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

Review 7.  Choosing patient-tailored hemodynamic monitoring.

Authors:  Cornelis Slagt; Rose-Marieke B G E Breukers; A B Johan Groeneveld
Journal:  Crit Care       Date:  2010-03-09       Impact factor: 9.097

Review 8.  Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review.

Authors:  Melina Dritsaki; Felix Achana; James Mason; Stavros Petrou
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

9.  Comparison of cardiac output determined by bioimpedance and bioreactance methods at rest and during exercise.

Authors:  Djordje G Jakovljevic; Sarah Moore; Kate Hallsworth; Gulnar Fattakhova; Christian Thoma; Michael I Trenell
Journal:  J Clin Monit Comput       Date:  2012-01-11       Impact factor: 2.502

10.  Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups.

Authors:  Maurizio Cecconi; Carlos Corredor; Nishkantha Arulkumaran; Gihan Abuella; Jonathan Ball; R Michael Grounds; Mark Hamilton; Andrew Rhodes
Journal:  Crit Care       Date:  2013-03-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.